The cancers most often linked to chemo are myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Sometimes, MDS occurs first, then turns into AML. Acute lymphocytic leukemia (ALL) has also been linked to chemo.

2018年12月20日 · Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000–2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML).

2019年9月9日 · Because some chemotherapy drugs can damage the DNA in the bone marrow, where leukemia forms, experts have assumed that the drugs trigger the formation of cancerous blood cells that lead to leukemia. A new study of people with breast cancer treated at Memorial Sloan Kettering is turning that idea on its head.

We present a case report and brief overview of the literature regarding chemotherapy-induced acute myeloid leukaemia (AML) following therapy for early stage breast cancer. Keywords: therapy-related leukaemia, breast cancer, adjuvant chemotherapy.

Leukemia as a secondary cancer can occur following treatment with chemotherapy. Although acute myelogenous leukemia is the most common type of therapy-related leukemia, acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) have also been reported.

2011年2月17日 · Therapy-related acute myeloid leukemia (t-AML) is a recognized clinical syndrome occurring as a complication after cytotoxic and/or radiation therapy. 1-3 At present, approximately 10% of all AMLs arise after a patient's exposure to chemotherapy and/or radiation for a primary malignancy or autoimmune disease. 4,5 Patients with t-AML are ...

In patients deemed fit, t-AML treatment can involve CPX-351 (liposomal daunorubicin and cytarabine) or conventional chemotherapy, ideally followed by hematopoietic cell transplantation. Patients who are not candidates for intensive therapy may benefit from lower-intensity therapies.

2013年2月27日 · Persons who have undergone cytotoxic chemotherapy for certain cancers, notably non-Hodgkin lymphoma, may be at risk for developing acute myeloid leukemia (AML).

2018年1月10日 · Older patients with non-metastatic breast cancer who have been treated modern chemotherapy drugs have a greater risk of secondary acute myeloid leukemia (AML) and/or myelodysplastic syndrome (MDS), according to researchers at MD Anderson Cancer Center.

Several chemotherapy agents that include alkylating agents, topoisomerase inhibitors, and tax anew are associated with the development of acute myelogenous leukemia and myelodysplastic syndrome. Alkylating agents and topoisomerase II inhibitors induce therapy related leukemia.